[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620214":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":24,"id":50,"slug":24,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":24,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":24,"enrollmentInfo":58,"targetDuration":24,"studyType":61,"phases":62,"briefSummary":65,"conditions":66,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"3H Pharmaceuticals Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stage I - dose escalation","EXPERIMENTAL","Dose escalation of 3H-10000 in patients with advanced solid tumors.",[13],"Drug: 3H-10000",{"label":15,"type":10,"description":16,"interventionNames":17},"stage II - expansion","Expansion evaluating the recommended dose and schedule of 3H-10000 identified from Stage I.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","3H-10000","3H-10000 will be administered by infusion Q2W in 28-day cycles.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Shuchao Wu","CONTACT","0086-21-50895559","shuchao.wu@3hpharma.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":24,"phoneExt":24,"email":24},"Lin Shen, MD",{"type":49,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100620214",false,"NCT07354711","A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","A Phase I\u002FII Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors","Inclusion Criteria:\n\n* Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.\n* Male or female subjects aged ≥18 years at the time of signing the ICF.\n* According to RECIST v1.1, there is at least one measurable lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.\n* Life expectancy of ≥3 months.\n\nExclusion Criteria:\n\n* Meningeal diseases or carcinomatous meningitis.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.\n* Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.\n* Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the investigator as not being associated with any safety risk).\n* Any corneal or retinal disease\u002Fkeratopathy assessed by the investigator as of clinical significance, including but not limited to bullous\u002Fband keratopathy, corneal abrasion, inflammation\u002Fulceration, and keratoconjunctivitis.","ALL","18 Years",{"count":59,"type":60},170,"ESTIMATED","INTERVENTIONAL",[63,64],"PHASE1","PHASE2","The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .",[67,68],"Lung Cancer","Stomach Cancer","2026-01-18",{"date":71,"type":72},"2026-01-21","ACTUAL",{"date":74,"type":72},"2026-01-04",{"date":76,"type":60},"2029-01",{"name":5,"class":6},1]